NASDAQ:INKT MiNK Therapeutics (INKT) Stock Price, News & Analysis $15.02 -0.44 (-2.85%) Closing price 04:00 PM EasternExtended Trading$14.86 -0.16 (-1.07%) As of 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About MiNK Therapeutics Stock (NASDAQ:INKT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get MiNK Therapeutics alerts:Sign Up Key Stats Today's Range$14.56▼$15.4250-Day Range$12.06▼$18.7152-Week Range$4.56▼$76.00Volume31,417 shsAverage Volume349,250 shsMarket Capitalization$67.94 millionP/E RatioN/ADividend YieldN/APrice Target$37.50Consensus RatingHold Company Overview MiNK Therapeutics, Inc. is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors. MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance. The company has established scalable, GMP‐compatible manufacturing processes to produce engineered exosomes at clinically relevant volumes. Research efforts focus on optimizing biodistribution, payload loading efficiency and safety profiles in animal models, with the goal of advancing IND‐enabling studies for first‐in‐human trials. Headquartered in Cambridge, Massachusetts, MiNK collaborates with academic institutions and contract development organizations across North America and Europe to accelerate its research and development programs. The company’s integrated operations encompass discovery, preclinical testing and process development, supported by a team of experts in exosome biology, translational immunology and biomanufacturing. Through these partnerships and internal capabilities, MiNK aims to bring novel, precision immunotherapies to patients with high‐unmet‐need solid tumors.AI Generated. May Contain Errors. Read More MiNK Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreINKT MarketRank™: MiNK Therapeutics scored higher than 52% of companies evaluated by MarketBeat, and ranked 462nd out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingMiNK Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, 1 hold rating, and 2 sell ratings.Upside PotentialMiNK Therapeutics has a consensus price target of $37.50, representing about 149.7% upside from its current price of $15.02.Amount of Analyst CoverageMiNK Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about MiNK Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for MiNK Therapeutics are expected to grow in the coming year, from ($2.75) to ($2.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MiNK Therapeutics is -5.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MiNK Therapeutics is -5.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about MiNK Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.55% of the float of MiNK Therapeutics has been sold short.Short Interest Ratio / Days to CoverMiNK Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MiNK Therapeutics has recently increased by 1.03%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMiNK Therapeutics does not currently pay a dividend.Dividend GrowthMiNK Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.55% of the float of MiNK Therapeutics has been sold short.Short Interest Ratio / Days to CoverMiNK Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MiNK Therapeutics has recently increased by 1.03%, indicating that investor sentiment is decreasing. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for MiNK Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for INKT on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows2 people have added MiNK Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, MiNK Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders22.48% of the stock of MiNK Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 2.87% of the stock of MiNK Therapeutics is held by institutions.Read more about MiNK Therapeutics' insider trading history. Receive INKT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MiNK Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INKT Stock News HeadlinesMiNK Therapeutics appoints John Holcomb to board of directorsSeptember 29, 2025 | msn.comMiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of DirectorsSeptember 29, 2025 | globenewswire.comGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter that... Treasury Secretary Bessent could move to officially revalue gold – exactly the scenario I've been warning about as part of the "Mar-a-Lago Accord."October 3 at 2:00 AM | Stansberry Research (Ad)MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MASeptember 25, 2025 | globenewswire.comAnalysts Set MiNK Therapeutics, Inc. (NASDAQ:INKT) Price Target at $37.50September 22, 2025 | americanbankingnews.comMiNK Therapeutics appoints Hammond as Head of Inflammatory, Pulmonary DiseasesSeptember 18, 2025 | msn.comMiNK Therapeutics Appoints Dr. Terese Hammond to Head Inflammatory and Pulmonary Diseases as it Prepares for Grant-Funded Clinical Trials in GVHD and Severe Pulmonary Inflammatory DiseaseSeptember 18, 2025 | quiverquant.comQMiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal DevelopmentSeptember 18, 2025 | globenewswire.comSee More Headlines INKT Stock Analysis - Frequently Asked Questions How have INKT shares performed this year? MiNK Therapeutics' stock was trading at $6.9690 on January 1st, 2025. Since then, INKT shares have increased by 115.5% and is now trading at $15.02. How were MiNK Therapeutics' earnings last quarter? MiNK Therapeutics, Inc. (NASDAQ:INKT) issued its quarterly earnings data on Thursday, August, 14th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.55) by $0.51. Read the conference call transcript. When did MiNK Therapeutics' stock split? MiNK Therapeutics's stock reverse split on the morning of Tuesday, January 28th 2025.The 1-10 reverse split was announced on Tuesday, January 21st 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 27th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did MiNK Therapeutics IPO? MiNK Therapeutics (INKT) raised $43 million in an initial public offering (IPO) on Friday, October 15th 2021. The company issued 3,333,334 shares at a price of $12.00-$14.00 per share. How do I buy shares of MiNK Therapeutics? Shares of INKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of MiNK Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that MiNK Therapeutics investors own include Agenus (AGEN), HubSpot (HUBS), Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA) and Bank of America (BAC). Company Calendar Last Earnings8/14/2025Today10/03/2025Next Earnings (Estimated)11/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:INKT CIK1840229 Webwww.minktherapeutics.com Phone212-994-8250FaxN/AEmployees30Year Founded2017Price Target and Rating Average Price Target for MiNK Therapeutics$37.50 High Price Target$40.00 Low Price Target$35.00 Potential Upside/Downside+149.7%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($2.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$9.51 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-227.24% Debt Debt-to-Equity RatioN/A Current Ratio0.15 Quick Ratio0.15 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($4.94) per share Price / Book-3.04Miscellaneous Outstanding Shares4,523,000Free Float3,506,000Market Cap$67.94 million OptionableNo Data Beta0.33 Social Links Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:INKT) was last updated on 10/3/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredRIP USA"The America you knew is dying in front of you" That's the urgent warning the former $200 million hedge fun...Stansberry Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | SponsoredIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MiNK Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MiNK Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.